SCOPUS 정보 검색 플랫폼

Volumn 5, Issue 3, 2012, Pages

Warfarin utilization in medicare patients with nonvalvular atrial fibrillation: Sentinel data from an administrative claims database

(1) Murphy, Michael F a

a Worldwide Clinical Trials ^* (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; CLINICAL PRACTICE; COST CONTROL; DRUG EFFICACY; DRUG UTILIZATION; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MEDICARE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PROTHROMBIN TIME; RISK BENEFIT ANALYSIS; RISK REDUCTION; STROKE;

EID: 84863824442 PISSN: 19422962 EISSN: 19422970 Source Type: Journal
DOI: None Document Type: Article

Times cited : (1)

References (7)

1
- 77957699729
- European Association for Cardio-Thoracic Surgery
- European Heart Rhythm Association; Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)
- European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-2429.
- (2010) Eur Heart J. , vol.31 , pp. 2369-2429

2
- 0034627893
- Why do patients with atrial fibrillation not receive warfarin?
- Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med. 2000;160:41-46.
- (2000) Arch Intern Med. , vol.160 , pp. 41-46
- Bungard, T.J.¹ Ghali, W.A.² Teo, K.K.³

3
- 80052836882
- A new era for anticoagulation in atrial fibrillation
- Mega JL. A new era for anticoagulation in atrial fibrillation. N Engl J Med. 2011; 365:1052-1054.
- (2011) N Engl J Med. , vol.365 , pp. 1052-1054
- Mega, J.L.¹

4
- 84863981277
- Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation
- Apr 24. [Epub ahead of print]
- Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012 Apr 24. [Epub ahead of print].
- (2012) Am J Cardiol.
- Miller, C.S.¹ Grandi, S.M.² Shimony, A.³

5
- 79451472118
- Cost efficiency of anticoagulation with warfarin to prevent stroke in Medicare beneficiaries with nonvalvular atrial fibrillation
- Mercaldi CJ, Ciarametaro M, Hahn B, et al. Cost efficiency of anticoagulation with warfarin to prevent stroke in Medicare beneficiaries with nonvalvular atrial fibrillation. Stroke. 2011;42:112-118.
- (2011) Stroke , vol.42 , pp. 112-118
- Mercaldi, C.J.¹ Ciarametaro, M.² Hahn, B.³

6
- 27144458795
- Economic burden and comorbidities of atrial fibrillation in a privately insured population
- Wu EQ, Birnbaum HG, Mareva M, et al. Economic burden and comorbidities of atrial fibrillation in a privately insured population. Curr Med Res Opin. 2005;21: 1693-1699.
- (2005) Curr Med Res Opin. , vol.21 , pp. 1693-1699
- Wu, E.Q.¹ Birnbaum, H.G.² Mareva, M.³

7
- 70449615579
- Epidemiology and economic burden of atrial fibrillation
- Bajpai A, Savelieva I, Camm AJ. Epidemiology and economic burden of atrial fibrillation. US Cardiovascular Dis. 2007;4:14-17
- (2007) US Cardiovascular Dis. , vol.4
- Bajpai, A.¹ Savelieva, I.² Camm, A.J.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.